[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Olszewski U, Zeillinger R, Geissler K, Hamilton G: Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells. Lung Cancer (Auckl); 2010;1:107-117
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells.
  • This study involved a comparison of the genome-wide gene expression pattern of a chemoresistant and a chemosensitive pulmonary carcinoid cell line to reveal factors that contribute to the resistant phenotype.
  • MATERIALS AND METHODS: Gene expression of UMC-11 chemoresistant carcinoid cells as assessed by 32 K microarray was compared with H835 chemosensitive carcinoid cells, and the genes that were differentially expressed and expected to be related to chemoresistance were selected.
  • RESULTS: Drug-resistant UMC-11 cells exhibited increased expression of transcripts known to confer resistance to different cytostatics such as P-glycoprotein, multidrug resistance-associated proteins 2 and 3, effectors of the glutathione detoxification and xenobiotics degradation pathways, and ion transporters including Na<sup>+</sup>/K<sup>+</sup>-adenosine triphosphatase.
  • In addition, enhanced transcription of several S100 proteins, capable of suppressing apoptosis, regulation of topoisomerase I (topo I) expression by antisense transcripts from <i>TOPO1</i> pseudogenes, and alterations of the cytoskeleton seem to contribute to the multidrug-resistant phenotype.
  • CONCLUSION: The multidrug-resistant phenotype of the UMC-11 pulmonary carcinoid cell line seems to be mediated by classical efflux pumps, drug metabolization or conjugation systems, and, possibly, modulation of apoptotic cell death by S100 proteins and topo I expression by pseudogene transcripts.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2003 Jul;186(1):28-31 [12842744.001]
  • [Cites] Cancer Cell Int. 2007 May 08;7:8 [17488522.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Feb;290(2):F241-50 [16403837.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):142-6 [16357535.001]
  • [Cites] Oncologist. 2005 Feb;10(2):123-31 [15709214.001]
  • [Cites] Mini Rev Med Chem. 2002 Jun;2(3):261-9 [12370067.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Jan;7(1):19-34 [17266503.001]
  • [Cites] Peptides. 2003 Jan;24(1):163-77 [12576099.001]
  • [Cites] Trends Biochem Sci. 2009 Oct;34(10):520-31 [19748784.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1693-8 [11245485.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:263-92 [16970545.001]
  • [Cites] Carcinogenesis. 2008 Sep;29(9):1675-84 [18632755.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1255-69 [19091780.001]
  • [Cites] Recent Results Cancer Res. 2010;180:15-34 [20033376.001]
  • [Cites] Ann Thorac Surg. 2010 Mar;89(3):998-1005 [20172187.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):316-24 [20029418.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):116-24 [2562856.001]
  • [Cites] Cancer. 2009 Oct 1;115(19):4434-41 [19562772.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):480-7 [10690527.001]
  • [Cites] Oncology. 2004;66(6):429-38 [15452371.001]
  • [Cites] Expert Opin Ther Targets. 2008 Nov;12(11):1403-17 [18851696.001]
  • [Cites] Int J Mol Med. 2005 Dec;16(6):1021-8 [16273281.001]
  • [Cites] Clin Lung Cancer. 2009 Jul;10(4):262-72 [19632946.001]
  • [Cites] Mol Cell Biochem. 1999 Jul;197(1-2):179-85 [10485337.001]
  • [Cites] Respir Res. 2009 Feb 03;10:8 [19192276.001]
  • [Cites] Int J Biol Markers. 2009 Oct-Dec;24(4):282-5 [20082272.001]
  • [Cites] Mod Pathol. 2009 Feb;22(2):261-72 [18953328.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Jun;89(6):819-25 [2582209.001]
  • [Cites] J Pathol. 2006 Jun;209(2):147-56 [16691544.001]
  • [Cites] Anticancer Drugs. 2007 Jul;18(6):633-9 [17762391.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4897-904 [16051944.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):433-43 [16319398.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6041-6 [11983899.001]
  • [Cites] Pharmacogenomics. 2009 Mar;10(3):339-44 [19290786.001]
  • [Cites] Breast Cancer Res Treat. 2004 May;85(1):31-51 [15039596.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3524-30 [12839937.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4280-5 [1339303.001]
  • [Cites] Eur J Cardiothorac Surg. 1993;7(3):121-4; discussion 125 [8384862.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1329-35 [15920550.001]
  • [Cites] Cancer Detect Prev. 2000;24(1):53-60 [10757123.001]
  • [Cites] Mol Ther. 2010 Mar;18(3):528-35 [19826406.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Aug;1(3):201-7 [19138957.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Biol Pharm Bull. 2009 Jul;32(7):1148-54 [19571376.001]
  • [Cites] Cancer Treat Rev. 2009 Feb;35(1):18-31 [18771857.001]
  • [Cites] Cancer Res. 2010 May 1;70(9):3494-504 [20406980.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):727-40 [6199469.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3315-24 [19447869.001]
  • [Cites] Eur J Clin Invest. 2000 Aug;30(8):729-39 [10964166.001]
  • [Cites] Cell Mol Life Sci. 2007 Apr;64(7-8):830-49 [17310282.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2005;22:471-83 [16110625.001]
  • [Cites] Neuroendocrinology. 2009;89(1):66-78 [18708724.001]
  • [Cites] ACS Chem Biol. 2009 Jul 17;4(7):503-25 [19462983.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Feb;278(2):L407-16 [10666126.001]
  • [Cites] Clin Transl Oncol. 2011 Jan;13(1):43-9 [21239354.001]
  • [Cites] Biochim Biophys Acta. 2010 Apr;1805(2):141-52 [20122995.001]
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):146-9 [15075907.001]
  • [Cites] Surg Today. 1994;24(9):772-7 [7865952.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1215-33 [18217975.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14 ):6786-95 [17638890.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):649-55 [19130141.001]
  • [Cites] Int J Cancer. 1996 Jun 11;66(6):760-7 [8647646.001]
  • [Cites] Mol Aspects Med. 2009 Feb-Apr;30(1-2):13-28 [18786560.001]
  • [Cites] J Biol Chem. 2010 Jun 11;285(24):18452-63 [20207735.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Mar;63(4):643-50 [18545997.001]
  • [Cites] Nature. 1995 Apr 27;374(6525):811-3 [7723826.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1069-84 [17158754.001]
  • [Cites] J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S152-9 [18520302.001]
  • [Cites] Biol Chem. 2010 Apr;391(4):299-310 [20180639.001]
  • [Cites] Carcinogenesis. 1991 Dec;12(12):2301-3 [1747931.001]
  • [Cites] Panminerva Med. 2006 Mar;48(1):19-26 [16633328.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Dec;3(6):863-77 [14686708.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1970-6 [15545974.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2739-47 [19293189.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 1):C347-55 [9486123.001]
  • [Cites] Cancer Lett. 2009 Sep 8;282(1):30-4 [19339106.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Cancer. 1961 Sep-Oct;14:901-12 [13771655.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34226-36 [12815063.001]
  • (PMID = 28210111.001).
  • [Journal-full-title] Lung Cancer (Auckland, N.Z.)
  • [ISO-abbreviation] Lung Cancer (Auckl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; apoptosis / drug resistance / drug transporter / microarray / neuroendocrine tumor
  •  go-up   go-down


2. Chan HY, Grossman AB, Bukowski RM: Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Adv Ther; 2010 Aug;27(8):495-511
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Everolimus is an oral rapamycin derivative within the mammalian target of rapamycin class of agents.
  • A phase 3 placebo-controlled study in advanced clear-cell RCC, known as RECORD-1 (for "REnal Cell cancer treatment with Oral RAD001 given Daily"), documented that everolimus stabilizes tumor progression, prolongs progression-free survival and has acceptable tolerability in patients previously treated with the multikinase inhibitors sunitinib and/or sorafenib.
  • Forthcoming data from phase 3 placebo-controlled trials of everolimus, one focused on monotherapy for pancreatic NET and the other on combination use with octreotide LAR for patients with advanced NET and a history of carcinoid syndrome, will provide insight into its future place in NET therapy.
  • The results of a number of ongoing phase 3 evaluations of everolimus will determine its broader applicability in treating breast cancer (in combination with chemotherapy and hormonal therapy), several advanced gastrointestinal cancers, hepatocellular carcinoma, and lymphoma (in the adjuvant setting), as well as the various lesions associated with the tuberous sclerosis complex tumor suppressor gene.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy. Protein Kinase Inhibitors / therapeutic use. Sirolimus
  • [MeSH-minor] Clinical Trials, Phase III as Topic. Disease-Free Survival. Drug Therapy, Combination. Humans. Molecular Targeted Therapy. Octreotide / therapeutic use. Practice Guidelines as Topic. TOR Serine-Threonine Kinases / antagonists & inhibitors. TOR Serine-Threonine Kinases / metabolism


3. de Vries HS, van Oijen MG, de Jong DJ: Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf; 2008;31(12):1135-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine patients (6%) developed malignancies during follow-up: four colorectal carcinomas, one carcinoid tumour with another primary signet-ring cell carcinoma of the small bowel, one breast cancer, two skin cancers and one superficial melanoma.
  • CONCLUSION: Clinicians prescribing biological therapies should be aware of the development of serious events in their patients.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Gastrointestinal Agents / adverse effects. Hospitalization / statistics & numerical data. Inflammatory Bowel Diseases / drug therapy
  • [MeSH-minor] Adult. Causality. Cohort Studies. Female. Humans. Infliximab. Length of Stay. Male. Neoplasms / chemically induced. Neoplasms / epidemiology. Netherlands / epidemiology. Retrospective Studies. Surgical Procedures, Operative / statistics & numerical data. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2002 Dec;97(12):2962-72 [12492177.001]
  • [Cites] Gut. 2004 Jun;53(6):849-53 [15138212.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1641-57 [17499606.001]
  • [Cites] World J Gastroenterol. 2008 Jan 21;14(3):378-89 [18200660.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7 [17255842.001]
  • [Cites] N Engl J Med. 2003 Feb 13;348(7):601-8 [12584368.001]
  • [Cites] Gut. 2006 Jun;55(6):749-53 [16698746.001]
  • [Cites] JAMA. 2006 May 17;295(19):2275-85 [16705109.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Sep;13 Suppl 4:16-22; discussion 38 [10597335.001]
  • [Cites] J Clin Gastroenterol. 2009 Apr;43(4):387-8 [18987555.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1315-24 [12818276.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1161-8 [9609752.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2462-76 [16339095.001]
  • [Cites] Neth J Med. 2006 Jul-Aug;64(7):219-29 [16929083.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):577-94 [18242222.001]
  • [Cites] Rheumatology (Oxford). 2005 Jun;44(6):714-20 [15741198.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):862-9 [15825070.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):761-9 [10500056.001]
  • [Cites] World J Gastroenterol. 2008 May 7;14(17):2662-9 [18461651.001]
  • [Cites] Thorax. 2007 Nov;62(11):1013-4 [17965080.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):427-34 [17653185.001]
  • [Cites] Dig Dis Sci. 2007 Jun;52(6):1481-4 [17429728.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):769-79 [17628557.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Sep 16;144(38):1844-5 [11020841.001]
  • [Cites] Drug Saf. 2000 Nov;23(5):429-48 [11085348.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1808-14 [12055588.001]
  • [Cites] J Infect. 2007 Dec;55(6):484-7 [17920687.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):929-36 [18294633.001]
  • [Cites] N Engl J Med. 2004 Feb 26;350(9):876-85 [14985485.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):621-30 [16678077.001]
  • (PMID = 19026030.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


Advertisement
4. Namasivayam S, Martin DR, Saini S: Imaging of liver metastases: MRI. Cancer Imaging; 2007;7:2-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific characterization of liver metastases in patients with primary non-hepatic tumors is crucial to avoid unnecessary diagnostic work-up for incidental benign liver lesions.
  • MR contrast agents provide critical tumor characterization and can be safely used in patients with iodine contrast allergy and renal failure.
  • Other agents, including newly developing gadolinium-chelates or iron oxide agents may provide additional benefits in selected applications.
  • The degree and nature of tumor vascularity form the basis for liver lesion characterization based on enhancement properties.
  • Colon, lung, breast and gastric carcinomas are the most common tumors causing hypovascular liver metastases, and typically show perilesional enhancement.
  • Neuroendocrine tumors including carcinoid and islet cell tumors, renal cell carcinoma, breast, melanoma, and thyroid carcinoma are tumors most commonly causing hypervascular hepatic metastases, which may develop early enhancement with variable degrees of washout and peripheral rim enhancement.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1407-13 [7484575.001]
  • [Cites] Radiology. 1995 Aug;196(2):471-8 [7617863.001]
  • [Cites] Radiology. 1996 Mar;198(3):881-7 [8628887.001]
  • [Cites] Radiology. 1996 May;199(2):513-20 [8668804.001]
  • [Cites] Radiology. 1996 Jul;200(1):59-67 [8657946.001]
  • [Cites] Radiology. 1996 Sep;200(3):785-92 [8756932.001]
  • [Cites] J Magn Reson Imaging. 1996 Mar-Apr;6(2):291-4 [9132092.001]
  • [Cites] Eur Radiol. 1997;7(2):275-80 [9038130.001]
  • [Cites] Radiology. 1997 May;203(2):449-56 [9114103.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):626-30 [9245955.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 2):631-7 [9245956.001]
  • [Cites] Radiol Clin North Am. 1998 Mar;36(2):287-97 [9520982.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2005 May;13(2):241-54, v-vi [15935310.001]
  • [Cites] Radiol Clin North Am. 2005 Sep;43(5):861-86, viii [16098344.001]
  • [Cites] Cancer Imaging. 2005;5 Spec No A:S149-56 [16361131.001]
  • [Cites] AJR Am J Roentgenol. 2006 Apr;186(4):1051-8 [16554578.001]
  • [Cites] Radiology. 2006 Apr;239(1):122-30 [16493012.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1337-45 [16453115.001]
  • [Cites] Cancer Imaging. 2006;6:33-42 [16766267.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1898-905 [16691378.001]
  • [Cites] Radiology. 1999 Oct;213(1):86-91 [10540645.001]
  • [Cites] Radiology. 2000 Apr;215(1):89-94 [10751472.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2000 Nov;8(4):741-56 [11149677.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):73-90 [11933597.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):165-79, vii [11933587.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jul;151(1):79-84 [3259825.001]
  • [Cites] Radiology. 1992 Jan;182(1):167-74 [1309218.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jan-Feb;17(1):67-74 [8419443.001]
  • [Cites] Radiology. 1994 Dec;193(3):657-63 [7972804.001]
  • [Cites] Radiology. 1995 Dec;197(3):575-7 [7480718.001]
  • (PMID = 17293303.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC1804118
  •  go-up   go-down


5. Rothermel J, Wartmann M, Chen T, Hohneker J: EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol; 2003 Jun;30(3 Suppl 6):51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EPO906 (epothilone B) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones.
  • Importantly, in contrast to the taxanes, EPO906 retained activity against cancer cells either overexpressing the P-glycoprotein efflux pump or bearing tubulin mutations.
  • Tumor responses were seen in colorectal cancer as well as a variety of other tumor types, such as breast, ovarian, lung, and carcinoid in these two phase I trials.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Epothilones / pharmacology. Microtubules / drug effects
  • [MeSH-minor] Animals. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor. Humans

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12802795.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epothilones; UEC0H0URSE / epothilone B
  • [Number-of-references] 22
  •  go-up   go-down


6. Gilbert JA, Frederick LM, Ames MM: The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res; 2000 Nov;6(11):4365-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.
  • The carcinoid tumor is an uncommon neuroendocrine neoplasm the hallmark of which is excessive serotonin production.
  • In studying kinetics of tryptophan hydroxylase and aromatic-L-amino acid decarboxylase (AAAD) in human carcinoid hepatic metastases and adjacent normal liver (J. A.
  • Pharmacol., 50: 845-850, 1995), we identified one significant difference: the Vmax of carcinoid AAAD was 50-fold higher than that in normal liver.
  • Here, we report Western and Northern analyses detecting large quantities of AAAD polypeptide and mRNA in human carcinoid primary as well as metastatic tumors compared with normal surrounding tissues.
  • To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.
  • On exposure to other human tumor lines, carbidopa was lethal only to NCI-H146 and NCI-H209 small cell lung carcinoma (SCLC) lines (IC50 = 12 +/- 1 microM and 22 +/- 5 microM, respectively).
  • Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines.
  • For lung tumor lines (carcinoid, two SCLC, and one large cell lung carcinoma), AAAD activity was correlated with the potency of carbidopa-induced cytotoxicity.
  • However, carcinoid cell death was not solely attributable to complete inhibition of either AAAD activity or the serotonin synthetic pathway.
  • In further evaluating potential applications of these findings with carbidopa, we determined that sublethal doses of carbidopa produced additive cytotoxic effects in carcinoid cells in combination with etoposide and cytotoxic synergy in SCLC cells when coincubated with topotecan.
  • [MeSH-major] Aromatic Amino Acid Decarboxylase Inhibitors. Carbidopa / pharmacology. Carcinoid Tumor / drug therapy. Carcinoma, Small Cell / drug therapy. Enzyme Inhibitors / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Cell Division / drug effects. Humans. Ileum / enzymology. Liver / enzymology. Microscopy, Electron. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11106255.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 58450
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Aromatic Amino Acid Decarboxylase Inhibitors; 0 / Enzyme Inhibitors; MNX7R8C5VO / Carbidopa
  •  go-up   go-down






Advertisement